Research analysts at Cowen and Company started coverage on shares of Proteon Therapeutics Inc. (NASDAQ:PRTO) in a research note issued on Wednesday. The firm set an “outperform” rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also commented on the stock. HC Wainwright started coverage on shares of Proteon Therapeutics in a research report on Thursday, September 22nd. They issued a “buy” rating and a $18.00 price objective for the company. Zacks Investment Research upgraded shares of Proteon Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, October 12th. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $20.80.

Analyst Recommendations for Proteon Therapeutics (NASDAQ:PRTO)

Proteon Therapeutics (NASDAQ:PRTO) opened at 9.00 on Wednesday. The firm’s market capitalization is $149.24 million. Proteon Therapeutics has a 12 month low of $4.90 and a 12 month high of $17.76. The firm has a 50-day moving average of $8.94 and a 200 day moving average of $8.20.

Proteon Therapeutics (NASDAQ:PRTO) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by $0.05. Equities research analysts forecast that Proteon Therapeutics will post ($1.85) earnings per share for the current year.

Several large investors have recently made changes to their positions in PRTO. Deerfield Management Co. raised its stake in shares of Proteon Therapeutics by 22.7% in the second quarter. Deerfield Management Co. now owns 1,552,031 shares of the biopharmaceutical company’s stock worth $12,463,000 after buying an additional 286,688 shares during the last quarter. State Street Corp raised its stake in shares of Proteon Therapeutics by 58.8% in the first quarter. State Street Corp now owns 94,432 shares of the biopharmaceutical company’s stock worth $729,000 after buying an additional 34,952 shares during the last quarter. Paloma Partners Management Co acquired a new stake in shares of Proteon Therapeutics during the second quarter worth $234,000. TFS Capital LLC acquired a new stake in shares of Proteon Therapeutics during the second quarter worth $206,000. Finally, Bridgeway Capital Management Inc. raised its stake in shares of Proteon Therapeutics by 211.2% in the second quarter. Bridgeway Capital Management Inc. now owns 36,835 shares of the biopharmaceutical company’s stock worth $296,000 after buying an additional 25,000 shares during the last quarter. Hedge funds and other institutional investors own 51.54% of the company’s stock.

Proteon Therapeutics Company Profile

Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.

5 Day Chart for NASDAQ:PRTO

Receive News & Stock Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related stocks with our FREE daily email newsletter.